RxDoctor Payments Data

Kevin Singh, OD

Optometrist · Richmond Hill, NYNPI 1508437625

Payments from drug & device makers

$2,875in general payments, 2019–2025

Across 115 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$610
  • Bausch & Lomb Americas Inc.$457
  • AbbVie$310
  • Sun Pharmaceutical Industries Inc.$294
  • Alcon$284
  • Dompe US, Inc.$207
  • plus $712 from 8 others

What the payments were for

  • Food & beverage$2,85799%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,875 in reported general payments places this provider in the 80th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$48,112
Medicare patients
175
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine283$253,589
XiidraLifitegrast109$94,651
MieboPerfluorohexyloctane/Pf118$85,487
LumiganBimatoprost164$68,356
EysuvisLoteprednol Etabonate61$28,874
VyzultaLatanoprostene Bunod58$24,513
RocklatanNetarsudil Mesylat/Latanoprost71$24,226
CombiganBrimonidine Tartrate/Timolol81$22,143
XdemvyLotilaner11$19,914
Restasis MultidoseCyclosporine30$18,441
VevyeCyclosporine15$10,954
Cyclosporine24$9,910
ZerviateCetirizine Hcl26$8,133
SimbrinzaBrinzolamide/Brimonidine Tart36$7,391
RhopressaNetarsudil Mesylate12$5,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose$310$362,530558 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$457$204,651285 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$178$19,91411 claims
Harrow Eye, LLCVevye$163$10,95415 claims
AlconSimbrinza$284$7,39136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,743 optometrist providers in New York.

Other optometrist in Richmond Hill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →